SLS
Sellas Life Sciences Group IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$861.77M
P/E Ratio
—
EPS
$-0.25
Beta
2.23
52W High
$6.14
52W Low
$1.36
50-Day MA
$4.87
200-Day MA
$2.94
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the United States. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 900,000 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -66.90% |
| Return on Assets | -34.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.46 |
| Price-to-Book | 12.71 |
| Price-to-Sales (TTM) | 26.90 |
| EV/Revenue | 20.84 |
| EV/EBITDA | -1.71 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -82.50% |
| Shares Outstanding | $184.53M |
| Float | $178.78M |
| % Insiders | 0.43% |
| % Institutions | 20.08% |
Historical Volatility
HV 10-Day
75.22%
HV 20-Day
72.85%
HV 30-Day
99.40%
HV 60-Day
90.70%
HV Rank
77.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($10.00 target)
1
Strong Buy2
BuyData last updated: 4/30/2026